Back

Preclinical development of a Meg3 ASO inhibitor for the treatment of cardiac fibrosis

26 January 2026 (17:00 - 17:10)
Organised by: Logo
Seminar Presentation Part of: YIA posters session Fibrosis Delegate Premium access HFA Winter Research Meeting 2026 Heart Failure Association (HFA)

14 More presentations in this session

Presentation thumbnail
Class IIa HDACs Inhibition reverses diastolic dysfunction and Increase Energy Expenditure in a murine HFpEF model
Abstract Slides
Presentation thumbnail
The early metabolic cardiac targets of Empagliflozin during the development of heart failure, independent of SGLT2 inhibition
Abstract Slides
Presentation thumbnail
BET proteins link epigenetic remodeling to impaired autophagy in HFpEF
Abstract Slides
Presentation thumbnail
SDF-1/CXCR4 signaling promotes atrial fibrillation in heart failure with preserved ejection fraction
Abstract Slides
Presentation thumbnail
Cardiac metabolic alterations as a novel therapeutic target in doxorubicin toxicity
Abstract Slides

Access the full session

Session thumbnail
YIA posters session

The Event

Event poster

HFA Winter Research Meeting 2026

26 January 2026 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Silencing RNA to treat heart failure and cardiomyopathy
10 May 2026
thumbnail
Congress Presentation
Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study
21 May 2023
thumbnail
Congress Presentation
Towards advanced cardiac miRNA therapies through DNA-based nanostructures
29 April 2022
thumbnail
Congress Presentation
Mechanosensitive molecular mechanisms of myocardial fibrosis in living myocardial slices
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources